Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
2.
Nutr Cancer ; 64(6): 820-5, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22823889

RESUMEN

Oral consumption of freeze-dried black raspberries attenuated neoplastic changes in colorectal tissue markers of apoptosis, cell proliferation, and angiogenesis in colorectal cancer (CRC) patients. To determine whether plasma concentrations of interleukin (IL)-1ß, IL-2, IL-6, IL-8, IL-10, IL-12p70, granulocyte macrophage colony stimulating factor (GM-CSF), interferon-γ, and tumor necrosis factor-α (TNF-α) were associated with berry treatment and changes in colorectal tissue markers of apoptosis, cell proliferation, and angiogenesis, plasma and biopsy samples of adenocarcinoma and adjacent normal-appearing colorectal tissue were collected before and during berry treatment from 24 CRC patients who had not received prior therapy and drank a slurry of black raspberry powder (20 g in 100 ml drinking water) 3 times a day for 1 to 9 wk. Plasma concentrations of GM-CSF (+0.12 ± 0.04 pg/mL; P = 0.01) and IL-8 (-1.61 ± 0.71 pg/mL; P = 0.04) changed in patients receiving berries for more than 10 days. These changes were correlated with beneficial changes in markers of proliferation (r(ΔGM-CSF, ΔKi67 carcinoma - normal) = -0.51) and apoptosis (r(ΔIL-8, ΔTUNEL carcinoma - normal) = -0.52) observed in colorectal tissue taken within the same week. Plasma concentrations of GM-CSF and IL-8 may serve as noninvasive indicators to monitor tissue response to berry-based interventions for CRC.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Neoplasias Colorrectales/tratamiento farmacológico , Citocinas/sangre , Frutas , Rosaceae , Adenocarcinoma/sangre , Adenocarcinoma/dietoterapia , Adenocarcinoma/patología , Administración Oral , Adulto , Anciano , Apoptosis , Biomarcadores/sangre , Neoplasias Colorrectales/sangre , Neoplasias Colorrectales/dietoterapia , Neoplasias Colorrectales/patología , Femenino , Conservación de Alimentos , Liofilización , Factor Estimulante de Colonias de Granulocitos y Macrófagos/sangre , Humanos , Interferón gamma/sangre , Interleucina-8/sangre , Interleucinas/sangre , Masculino , Persona de Mediana Edad , Fitoterapia/métodos , Valor Predictivo de las Pruebas , Factor de Necrosis Tumoral alfa/sangre
3.
Cancer Prev Res (Phila) ; 3(4): 495-504, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20233899

RESUMEN

Signal transducer and activator of transcription 2 (STAT2) is an essential transcription factor in the type I IFN (IFN-alpha/beta) signal transduction pathway and known for its role in mediating antiviral immunity and cell growth inhibition. Unlike other members of the STAT family, IFNs are the only cytokines known to date that can activate STAT2. Given the inflammatory and antiproliferative dual nature of IFNs, we hypothesized that STAT2 prevents inflammation-induced colorectal and skin carcinogenesis by altering the inflammatory immune response. Contrary to our hypothesis, deletion of STAT2 inhibited azoxymethane/dextran sodium sulfate-induced colorectal carcinogenesis as measured by prolonged survival, lower adenoma incidence, smaller polyps, and less chronic inflammation. STAT2 deficiency also inhibited 7,12-dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-13-acetate-induced skin carcinogenesis as indicated by reduced papilloma multiplicity. A potential mechanism by which STAT2 promotes carcinogenesis is through activation of proinflammatory mediators. Deletion of STAT2 decreased azoxymethane/dextran sodium sulfate-induced expression and release of proinflammatory mediators, such as interleukin-6 and CCL2, and decreased interleukin-6 release from skin carcinoma cells, which then decreased STAT3 activation. Our findings identify STAT2 as a novel contributor to colorectal and skin carcinogenesis that may act to increase the gene expression and secretion of proinflammatory mediators, which in turn activate the oncogenic STAT3 signaling pathway.


Asunto(s)
Neoplasias Colorrectales/metabolismo , Factor de Transcripción STAT2/metabolismo , Transducción de Señal/fisiología , Neoplasias Cutáneas/metabolismo , Animales , Carcinógenos/toxicidad , Transformación Celular Neoplásica/metabolismo , Neoplasias Colorrectales/genética , Neoplasias Colorrectales/inmunología , Femenino , Expresión Génica , Regulación de la Expresión Génica/fisiología , Inmunohistoquímica , Inflamación/inducido químicamente , Inflamación/inmunología , Inflamación/metabolismo , Ratones , Ratones Noqueados , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factor de Transcripción STAT2/genética , Neoplasias Cutáneas/genética , Neoplasias Cutáneas/inmunología
4.
Cancer Prev Res (Phila) ; 2(1): 60-9, 2009 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19139019

RESUMEN

Although inflammatory cytokines and obesity-associated serum proteins have been reported as biomarkers of colorectal adenoma risk in humans, little is known of biomarkers of response to interventions that attenuate tumorigenesis. Dietary navy beans and their fractions attenuate colon carcinogenesis in carcinogen-induced genetically obese mice. We hypothesized that this attenuation would be associated with changes in inflammatory cytokines and obesity-related serum proteins that may serve as measures of efficacy. ob/ob mice (n = 160) were injected with the carcinogen azoxymethane (AOM) to induce colon cancer and randomly placed on one of four diets (control, whole navy bean, bean residue fraction, or bean extract fraction) for 26 to 28 wk. Serum was analyzed for 14 inflammation- or obesity-related proteins, and colon RNA was analyzed for expression of 84 inflammation-associated genes. Six of 14 serum proteins were increased [i.e., interleukin (IL)-4, IL-5, IL-6, IL-10, IFN gamma, granulocyte macrophage colony-stimulating factor] in hyperplastic/dysplastic stages of colon carcinogenesis. Bean-fed mice had significantly higher monocyte chemoattractant protein-1 and lower IL-6 levels in serum. In colon mucosa, 55 of 84 inflammation-associated genes differed between AOM-induced and noninduced mice. Of the 55 AOM-induced genes, 5 were counteracted by bean diets, including IL-6 whose increase in expression levels was attenuated by bean diets in AOM-induced mice. In summary, IL-6 emerged as a serum protein that was increased in hyperplastic/dysplastic stages of colon carcinogenesis, but attenuated with bean-based diet in serum and colon mucosa. Changes in a subset of inflammation-associated serum proteins and colon gene expression may serve as response indicators of dietary attenuation of colon carcinogenesis.


Asunto(s)
Neoplasias del Colon/dietoterapia , Citocinas/biosíntesis , Inflamación/metabolismo , Fitoterapia , Extractos Vegetales/administración & dosificación , Animales , Azoximetano/toxicidad , Biomarcadores de Tumor/análisis , Carcinógenos/toxicidad , Neoplasias del Colon/genética , Neoplasias del Colon/metabolismo , Citocinas/genética , Citocinas/metabolismo , Dieta , Fabaceae/química , Expresión Génica/efectos de los fármacos , Inflamación/genética , Interleucina-6/biosíntesis , Interleucina-6/genética , Masculino , Ratones , Ratones Obesos , Obesidad/complicaciones , Lesiones Precancerosas/dietoterapia , Lesiones Precancerosas/genética , Lesiones Precancerosas/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
5.
Nutr Cancer ; 60(3): 373-81, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18444172

RESUMEN

Based on the protective effects of cooked dry bean consumption in a human intervention study, we evaluated which fraction of cooked dry beans is responsible for its cancer-preventive effects. Cooked navy beans (whole beans), the insoluble fraction (bean residue) or soluble fraction of the 60% (vol:vol) ethanol extract of cooked navy beans (bean extract), or a modified AIN-93G diet (16.6% fat including 12.9% lard) as control diet were fed to 160 male obese ob/ob mice after 2 azoxymethane injections. In comparison to control-fed mice, dysplasia, adenomas, or adenocarcinomas were detected in fewer mice on either bean fraction diet (percent reduction from control: whole beans 54%, P=0.10; bean residue 81%, P=0.003; bean extract 91%, P=0.007), and any type of colon lesions, including focal hyperplasia, were found in fewer mice on each of the 3 bean diets percent reduction from control: whole bean 56%, P=0.04; bean residue 67%, P=0.01; bean extract 87%, P=0.0003. These results suggest that both the soluble and the insoluble fraction of the extract contribute to the cancer-protective effect of cooked navy beans.


Asunto(s)
Anticarcinógenos/farmacología , Azoximetano/antagonistas & inhibidores , Neoplasias del Colon/prevención & control , Fabaceae/química , Extractos Vegetales/farmacología , Adenocarcinoma/inducido químicamente , Adenocarcinoma/prevención & control , Adenoma/inducido químicamente , Adenoma/prevención & control , Animales , Anticarcinógenos/análisis , Azoximetano/toxicidad , Carcinógenos/antagonistas & inhibidores , Carcinógenos/toxicidad , Neoplasias del Colon/inducido químicamente , Masculino , Ratones , Ratones Obesos , Extractos Vegetales/análisis , Distribución Aleatoria , Solubilidad
6.
J Nutr ; 135(5): 989-95, 2005 May.
Artículo en Inglés | MEDLINE | ID: mdl-15867270

RESUMEN

Studies in vitro suggest that osteopontin (OPN), an extracellular matrix protein secreted by macrophages infiltrating prostate tumors, and by tumor cells, may have a role in the transition from clinically insignificant tumors to metastatic prostate cancer (PC). Latent PC occurs at equal rates in Western and Asian men, but the incidence of advanced PC is many-fold higher in Western men. Our earlier studies in TRAnsgenic Mouse Prostate adenocarcinoma (TRAMP) mice showed that genistein, an isoflavone found in soybeans, lowered the incidence of advanced PC. This suggested that lower intake of dietary soy may be one possible cause for higher incidence of advanced PC in Western men. The objective of the present study was to test the hypothesis that genistein may exert its preventive effect by inhibiting OPN expression. From 5 to 28 wk of age, 80, 68, and 30 TRAMP mice were fed AIN-76A diet containing 0, 250, or 500 mg genistein/kg body weight, respectively. Organ weights were measured. The steady-state level of OPN mRNA was evaluated by RT-PCR in a longitudinal study in 74 TRAMP and 32 nontransgenic litter mates (NTM). Administration of 250 and 500 mg genistein/kg AIN-76A improved survival (P = 0.008 and P = 0.005, respectively) and reduced mean weight of prostates with poorly differentiated cancer (PD) (P < 0.001), as well as the mean weight of periaortic lymph nodes (LN), although the latter was not significant. OPN was upregulated 10-fold in PD compared with prostates with a lower pathological score from TRAMP or NTM of any age (P = 0.003). OPN mRNA levels in the dorsolateral prostate and metastasis to LN were significantly correlated (r = 0.643; P = 0.00006). Genistein had a dose-dependent, significant inhibitory effect on OPN transcript levels in prostates displaying advanced prostate cancer (PD; score 6; P = 0.05). Studies are consistent with the possibility that dietary genistein may delay the progression from benign to malignant tumors by inhibiting OPN expression.


Asunto(s)
Adenocarcinoma/genética , Genisteína/farmacología , Neoplasias de la Próstata/genética , Sialoglicoproteínas/genética , Proteínas de Soja/uso terapéutico , Adenocarcinoma/tratamiento farmacológico , Animales , Dieta , Genisteína/administración & dosificación , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Osteopontina , Neoplasias de la Próstata/tratamiento farmacológico , ARN Mensajero/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
7.
Prostate ; 61(1): 26-34, 2004 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-15287091

RESUMEN

BACKGROUND: Apoptosis is disrupted in prostate tumor cells, conferring a survival advantage. p53 is a nuclear protein believed to regulate cancer progression, in part by inducing apoptosis. To test this possibility in future studies, the objective of the present study was to generate a transgenic mouse model expressing mutant p53 in the prostate (PR). METHODS: Transgene incorporation was tested using Southern analysis. Expression of mutant p53 protein was examined using immunofluorescence microscopy. Apoptosis in the PR was evaluated using the Tunnel method. RESULTS: A construct, consisting of the rat probasin promoter and a mutant human p53 fragment, was prepared and used to generate transgenic mice. rPB-mutant p53 transgene incorporation, as well as nuclear accumulation of mutant human p53 protein, was demonstrated. Prostatic intraepithelial neoplasia (PIN) III and IV were found in PR of 52-week old transgenic mice, whereas no pathological changes were found in the other organs examined. PR ability to undergo apoptosis following castration was reduced in rPB-mutant p53 mice as compared to non transgenic littermates. CONCLUSIONS: Transgenic rPB-mutant p53 mice accumulate mutant p53 protein in PR, resulting in neoplastic lesions and reduced apoptotic potential in the PR. Breeding rPB-mutant p53 mice with mice expressing an oncogene in their PR will be useful in examining interactions of multiple genes that result in progression of slow growing prostate tumors expressing oncogenes alone to metastatic cancer.


Asunto(s)
Apoptosis/genética , Transformación Celular Neoplásica/genética , Próstata/fisiología , Neoplasias de la Próstata/genética , Proteína p53 Supresora de Tumor/genética , Animales , Transformación Celular Neoplásica/metabolismo , Transformación Celular Neoplásica/patología , Modelos Animales de Enfermedad , Femenino , Humanos , Inmunohistoquímica , Etiquetado Corte-Fin in Situ , Masculino , Ratones , Ratones Transgénicos , Microscopía Fluorescente , Mutación , Orquiectomía , Próstata/citología , Próstata/metabolismo , Neoplasia Intraepitelial Prostática/genética , Neoplasias de la Próstata/metabolismo , Neoplasias de la Próstata/patología , Ratas , Proteína p53 Supresora de Tumor/biosíntesis , Proteína p53 Supresora de Tumor/fisiología
8.
J Nutr ; 132(3): 552S-558S, 2002 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11880592

RESUMEN

We investigated the potential of genistein, the primary isoflavone of soy, to protect against breast and prostate cancers in animal models. For mammary cancer studies, Sprague-Dawley rats were fed AIN-76A diet plus minus 250 mg genistein/kg diet. Dimethylbenz[a]anthracene was administered by gavage at d 50 postpartum to induce mammary tumors. Mammary cancer chemoprevention was demonstrated after prepubertal and combined prepubertal and adult genistein treatments but not after prenatal- or adult-only treatments, demonstrating that the timing of exposure to genistein is important for mammary cancer chemoprevention. The cellular mechanism of action was found to be mammary gland and cell differentiation, as shown by whole-mount analysis and beta-casein expression. An imprinting effect was shown for epidermal growth factor receptor expression in mammary terminal end buds. For prostate cancer studies, we used two models. The first was a chemically (N-methylnitrosourea) induced prostate cancer rat model. Genistein in the diet inhibited the development of invasive adenocarcinomas in a dose-dependent manner. The second model was a transgenic mouse model that resulted in spontaneously developing adenocarcinoma tumor of the prostate. Genistein in the diet reduced the incidence of poorly differentiated prostatic adenocarcinomas in a dose-dependent manner and down-regulated androgen receptor, estrogen receptor-alpha, progesterone receptor, epidermal growth factor receptor, insulin-like growth factor-I, and extracellular signal-regulated kinase-1 but not estrogen receptor-beta and transforming growth factor-alpha mRNA expressions. We conclude that dietary genistein protects against mammary and prostate cancers by regulating specific sex steroid receptors and growth factor signaling pathways.


Asunto(s)
Anticarcinógenos/farmacología , Genisteína/farmacología , Glándulas Mamarias Animales/efectos de los fármacos , Próstata/efectos de los fármacos , Adenocarcinoma/inducido químicamente , Adenocarcinoma/genética , Adenocarcinoma/prevención & control , Animales , Anticarcinógenos/administración & dosificación , Diferenciación Celular/efectos de los fármacos , Femenino , Genisteína/administración & dosificación , Humanos , Masculino , Neoplasias Mamarias Experimentales/prevención & control , Ratones , Ratones Transgénicos , Neoplasias de la Próstata/inducido químicamente , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/prevención & control , Ratas , Glycine max/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA